ECE2024 Poster Presentations Pituitary and Neuroendocrinology (120 abstracts)
Characterization of patients stopping GH therapy for childhood-onset growth hormone deficiency in belgium - luxemburg
Boutsen Laure 1 , Thomas Muriel 2 , Staels Willem 3 , Lysy Philippe 4 , Becker Marianne 5 , Anne Rochtus 6 , Boros Emese 7 , Kathleen De Waele 8 , Hilde Dotrement 9 , Parent Anne-Simone 10 , Daniel Klink 11 , Chivu Olimpia 12 , Massa Guy 13 , Beckers Dominique 1 , sylvia Depoorter 14 , Reynaert Nele 15 , Logghe Karl 16 & Jean De Schepper 17
1CHU UCL Namur, Pediatric Endocrinology, yvoir, Belgium; 2, Brussels; 3UZ Brussel, Brussels; 4Cliniques Universitaires Saint-Luc, Brussels, Belgium; 5Luxembourg, Luxembourg, Luxembourg; 6UZ Leuven, Leuven, Belgium; 7Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium; 8UZ Gent, Gent, Belgium; 9UZ Antwerpen, Edegem, Belgium; 10CHU de Liège, Liège, Belgium; 11ZNA Koniging Paola Kinderziekenhuis, Antwerpen, Belgium; 12Clinique CHC MontLègia, Liège, Belgium; 13Jessa Ziekenhuis, Hasselt, Belgium; 14AZ Sint-Jan, Brugge, Belgium; 15Ziekenhuis Oost-Limburg, Genk, Belgium; 16AZ Delta, Roeselare, Belgium; 17UZ Brussel, Pediatric Endocrinology, Brussel, Belgium
Background: Growth hormone deficiency (GHD) in children comes in different etiologies and can be either isolated or combined with other pituitary hormone deficiencies. The diversity in GHD types and the variable duration of GH therapy complicate assessments of long-term treatment outcome. We characterized GHD patients at the end of GH therapy in Belgium and Luxemburg and evaluated height and adiposity outcomes in relation to GHD type.
Methods: Anthropometric and clinical characteristics of children with GHD who stopped GH therapy between January 2019 and December 2021 were retrieved from the binational BeLUX database (BELGROW).
Results: In total, 179 (119 male and 60 female) patients stopped GH therapy after a median (P10; P90) duration of 6.8 (2.6; 12.9) years. Eight patients received GH therapy for less than 2 years. In total, 113 (63 %) patients had isolated GHD and 66 (37%) combined GHD. Forty-five had congenital GHD (i.e., identified structural or genetic cause), 45 acquired and 89 (50%) idiopathic. All diagnostic categories showed male preponderance (>66 %). Isolated GHD was most prevalent in idiopathic GHD (93.3 % vs 44.2 % in congenital vs 22.2 % in acquired GHD). Ten patients stopped GH therapy before 13 years of age. Ninety -two male and 25 female patients stopped GH therapy after the age of 16 years at a mean (SD) height of 171.2 (7.3) cm and 159.5 (8.9) cm, respectively. Their mean (SD) height (-1.05 (1.0) vs -1.11 (1.48)) and BMI (0.06 (1.65) vs 0.18 (1.5)) z-scores were comparable. In this subgroup older than 16 years, the 66 patients with isolated GHD had significantly (P= 0.016) lower height z-scores than the 51 patients with combined GHD (-1.28(1.06) vs.-0.78 (1.13). Mean height and BMI z-scores at the end of GH therapy in patients > 16 years were similar between congenital (n=29), acquired GHD (n=32) and idiopathic GHD (n=56), while mean duration of GH therapy was longest in congenital GHD (9.78 (4.3) vs 6.9 (3.8) vs 6.46(3.7) year; P=0.001).
Conclusion: In GHD patients stopping GH therapy in BeLUx, we see a two-fold male preponderance and 1.7-fold preponderance of isolated GHD. Less than 6 % discontinue GH therapy before 13 years or receive less than 2 years of treatment. In those discontinuing GH therapy after 16 years of age, the height was superior in patients with combined GHD.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more